

0040-4039(94)02244-5


A Short Synthesis of Bicyclic Dipeptides Corresponding to Xxx-L-Pro and Xxx-D-Pro Having Constrained *Cis*-Proline Amides

Timothy P. Curran* and Patrick M. McEnaney

Department of Chemistry, College of the Holy Cross, Worcester, MA 01610-2395 USA


Abstract: A short synthesis that generates two isomeric bicyclic dipeptides having constrained, *cis*-proline amide bonds has been developed. One of these bicyclic dipeptides corresponds to an Xxx-L-Pro dipeptide (17), while the other isomer corresponds to an Xxx-D-Pro dipeptide (18).

Unlike the other 19 common amino acids, which predominantly assume *trans*-amide conformations when incorporated into peptides and proteins, proline amides display an equal



tendency to assume both the *cis*- (1) and *trans*-amide (2) conformation.¹ Because only proline amides possess this conformational flexibility, it has been speculated that *cis-trans* proline isomerization plays many important biochemical roles, including controlling the rate of protein folding,² triggering receptor-mediated transmembrane signalling,³ providing a recognition element in peptide antigens,⁴ and regulating both the activation and breakdown of peptide hormones.⁵ Of potential utility in studying these biochemical events would be peptides that constrain proline to either the *cis*- or *trans*-amide conformation. Detailed here is a short synthesis that generates two isomeric, bicyclic dipeptides that covalently constrain the proline amide to the *cis* conformation.


The obvious approach for constraining an Xxx-Pro dipeptide is to tether the α carbons of the two amino acids using a linker Y, as shown in general structure 3. The synthesis and characterization of 4, in which an alkyl linker (Y=CH₂CH₂) is used to constrain the amide to the *cis* conformation, has recently been described by two groups.⁶ The target molecules in the present work are 5 and 6, which employ a lactam-methylene (CO-NH-CH₂) linker. An attractive



feature of this linker is that the lactam provides additional constraint to the bicyclic framework. The two isomers **5** and **6** differ in their configuration at the carbon bearing the carboxylic acid. In **5** the carboxylic acid has the configuration identical to that of L-proline, while in **6** the carboxylic acid has the configuration identical to that of D-proline. Thus, **5** is a constrained, *cis*-Xxx-L-Pro dipeptide, while **6** is a constrained, *cis*-Xxx-D-Pro dipeptide. Another attractive feature of the synthesis detailed below is that it generates a separable 1:1 mixture of derivatives of **5** and **6**.

To access these bicyclic dipeptides diethyl-2,2-pyrrolidinedicarboxylate (**7**, prepared in one step from 1,3-dibromopropane and diethylaminomalonate⁷) is first coupled to *N*- α -Cbz-*N*- β -Boc-L-aminoalanine (**8**, available commercially⁸ or prepared in two steps from Cbz-Asn-OH⁹)

Scheme 1



- a. 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, CH_2Cl_2 (54%).
 b. CF_3CO_2H , CH_2Cl_2 (100%). c. Et_3N , $CHCl_3$, reflux. d. H_2 , Pd-C, EtOH (c & d 88%).
 e. $LiOH$, H_2O , MeOH (62%). f. 4-Nitrophenol, DCC, CH_2Cl_2 (70%).
 g. CF_3CO_2H , CH_2Cl_2 . h. Pyridine (g & h 55%).

using a water soluble carbodiimide to generate dipeptide **9** (see Scheme 1). Initial attempts to generate the 7-membered ring lactam involved treating **9** with trifluoroacetic acid in CH_2Cl_2 to remove the Boc protecting group; the resulting amine salt **10** was then dissolved in a $CHCl_3$

solution containing excess Et_3N . After stirring for 24 h at 23 °C, no loss of the **10** was detected. However, when this solution was brought to reflux, **10** was lost and a single new product, identified as diketopiperazine **11**, was formed over the course of 48 h. Identification of **11** was based on two observations. First, the Cbz NH proton in the ^1H NMR spectrum of the product appears as a triplet, indicating that the NH is adjacent to a methylene¹⁰; second, the *trans* orientation of the ethyl ester and methyleneamine groups was indicated by the failure of **12** (prepared from **11** by removal of the Cbz group) to cyclize in a refluxing $\text{Et}_3\text{N}/\text{CHCl}_3$ solution. Formation of **11**, which does possess a constrained *cis*-proline amide, must be initiated by transfer of the Cbz group from the α -amine to the β -amine. It is intriguing to note that the rearrangement and cyclization leading to **11** produces only one of the two possible diketopiperazine isomers.

The ready formation of **11** indicated that to obtain the desired 5,7 ring system, the cyclization reaction would have to be performed under milder conditions. To accomplish this, **9** was treated with one equivalent of LiOH to effect a monohydrolysis and generate a 1:1 mixture of half esters **13** and **14**. Esterification of this mixture with DCC and 4-nitrophenol then afforded a 1:1 mixture of diesters **15** and **16**. Treatment of the **15** and **16** mixture with $\text{CF}_3\text{CO}_2\text{H}$ in CH_2Cl_2 , followed by addition of the resulting amine salts to anhydrous pyridine at 23 °C led to the formation of a 1:1 mixture of the isomeric bicyclic dipeptides **17** and **18**, which could be separated by flash chromatography.¹¹

The two isomers **17** and **18** display distinctly different ^1H NMR spectra¹¹ which facilitated their assignment. For one of the isomers the lactam NH proton appears as a doublet, indicating that the dihedral angle between the NH and one of the adjacent methylene protons is close to 90°. For the other isomer the lactam NH appears as a doublet of doublets, indicating that neither of the dihedral angles between the NH and the adjacent methylene protons is near 90°. Inspection of Dreiding models of both **17** and **18** shows that, of the two isomers, only **17** can assume a conformation having a nearly 90° dihedral angle between the NH and the adjacent methylene. Thus, the bicyclic dipeptide having the L-proline configuration at the ethyl ester




Figure 1. Low energy conformations of **17** and **18**. The carbons are darkly shaded, the nitrogens are lightly shaded, the oxygens are spotted and the hydrogens are white.

(17) possesses the amide NH that appears as a doublet, while the bicyclic dipeptide having the D-proline configuration at the ethyl ester (18) possesses the amide NH that appears as a triplet.

These assignments were confirmed by molecular modeling experiments in which low energy conformations of 17 and 18 (see Figure 1) were obtained using an MM2 energy minimization.¹² In the low energy conformation obtained for 17, the calculated dihedral angles between the lactam NH and the adjacent methylene protons are -86° and $+28^\circ$. For the low energy conformation obtained for 18, the calculated dihedral angles are -116° and -3° . Of the two isomers, only 17 shows a dihedral angle (-86°) close to 90° , in agreement with both the NMR and Dreiding model data.

Acknowledgments. This work was supported by a grant from the National Institutes of Health (NIH-AREA grant AR41568-01), and by a summer undergraduate research fellowship (1992) awarded to P.M.M. by the College of the Holy Cross under the auspices of a grant from the Howard Hughes Medical Institute. The NMR spectrometer used in the experiments was purchased with a grant from the National Science Foundation (NSF-ILI USE-8852774).

References and Notes.

1. Grathwohl, C.; Wuthrich, K. *Biopolymers* **1981**, *20*, 2623.
2. (a) Brandts, J.F.; Halvorson, H.R.; Brennan, M. *Biochemistry* **1975**, *14*, 953; For recent references see: (b) Borden, K.L.; Richards, F.M. *Biochemistry* **1990**, *29*, 3071; (c) Texter, F.L.; Spencer, D.B.; Rosenstein, R.; Matthews, C.R. *Biochemistry* **1992**, *31*, 5687; (d) Shalongo, W.; Jagannadham, M.V.; Heid, P.; Stellweg, E. *Biochemistry* **1992**, *31*, 11390; (e) Lang, K.; Schmid, F.X. *J. Mol. Biol.* **1990**, *212*, 185; (f) Kiefhaber, T.; Kohler, H.H.; Schmid, F.X. *J. Mol. Biol.* **1992**, *224*, 217; (g) Kiefhaber, T.; Kohler, H.H.; Schmid, F.X. *J. Mol. Biol.* **1992**, *224*, 231.
3. (a) Brandl, C.J.; Deber, C.M. *Proc. Natl. Acad. Sci. USA* **1986**, *83*, 917; (b) Williams, K.A.; Deber, C.M. *Biochemistry* **1991**, *30*, 8919; (c) Vogel, H.; Nilsson, L.; Rigler, R.; Meder, S.; Boheim, G.; Beck, W.; Kurth, H.H.; Jung, G. *Eur. J. Biochem.* **1993**, *212*, 305; (d) Wess, J.; Nanavati, S.; Vogel, Z.; Maggio, R. *EMBO J.* **1993**, *12*, 331; (e) Suchyna, T.M.; Xu, L.X.; Gao, F.; Fournier, C.R.; Nicholson, B.J. *Nature* **1993**, *365*, 847.
4. Richards, N.G.J.; Hinds, M.G.; Brennand, D.M.; Glennie, M.J.; Welsh, J.M.; Robinson, J.A. *Biochem. Pharm.* **1990**, *40*, 119.
5. (a) Yaron, A.; Naider, F. *Crit. Revs. Biochem. Mol. Biol.* **1993**, *28*, 31; (b) London, R.E.; Stewart, J.M.; Cann, J.R. *Biochem. Pharm.* **1990**, *40*, 41; (c) Yaron, A. *Biopolymers* **1987**, *26*, S215.
6. (a) Gramberg, D.; Robinson, J.A. *Tetrahedron Lett.* **1994**, *35*, 861; (b) Dumas, J.-P.; Germanas, J.P. *Tetrahedron Lett.* **1994**, *35*, 1493.
7. Van Heyningen, E. *J. Am. Chem. Soc.* **1954**, *76*, 3043.
8. Available from Bachem Bioscience, Inc., Catalog # C-3685.
9. Waki, M.; Kitajima, Y.; Izumiya, N. *Synthesis* **1981**, 266.
10. 11: ^1H NMR (300 MHz, CDCl_3) δ 7.34 (5H, s), 6.90 (1H, s, amide NH), 5.50 (1H, t, $J=6.2$ Hz), 5.10 (2H, 2d, $J=12$ Hz), 4.27 (2H, m), 4.17 (1H, t, $J=3.6$ Hz), 3.81 (1H, m), 3.69 (1H, m), 3.64 (2H, m), 2.61 (1H, m), 2.44 (1H, m), 1.94 (2H, m), 1.30 (3H, t, $J=7.0$ Hz). MS (Cl^+ , CH_4) 430 ($\text{M}+\text{C}_3\text{H}_5$) $^+$, 418 ($\text{M}+\text{C}_2\text{H}_5$) $^+$, 390 ($\text{M}+\text{H}$) $^+$, 346 ($\text{M}-\text{NHCO}$) $^+$. TLC (2:1 EtOAc/hexane) $R_f=0.26$.
11. 17 and 18 are separable by flash chromatography (3:1 EtOAc/hexane). 17: ^1H NMR (300 MHz, CDCl_3) δ 7.35 (5H, s), 6.20 (1H, d, $J=4.4$ Hz), 6.11 (1H, d, $J=4.9$ Hz), 5.10 (2H, 2d, $J=13$ Hz), 4.57 (1H, m), 4.34 (2H, m), 3.85 (1H, m), 3.70 (1H, m), 3.58 (1H, m), 3.28 (1H, m), 3.01 (1H, m), 2.41 (1H, m), 1.87 (2H, m), 1.32 (3H, t, $J=7.3$ Hz). MS (Cl^+ , CH_4) 418 ($\text{M}+\text{C}_2\text{H}_5$) $^+$, 390 ($\text{M}+\text{H}$) $^+$, 346 ($\text{M}-\text{NHCO}$) $^+$. TLC (3:1 EtOAc/hexane) $R_f=0.30$.
18: ^1H NMR (300 MHz, CDCl_3) δ 7.35 (5H, s), 6.37 (1H, dd, $J=6.4, 5.9$ Hz), 5.66 (1H, d, $J=3.4$ Hz), 5.11 (2H, 2d, $J=12$ Hz), 4.30 (2H, m), 4.23 (1H, m), 3.88 (1H, m), 3.72 (2H, m), 3.16 (1H, m), 3.00 (1H, m), 2.24 (1H, m), 1.84 (2H, m), 1.30 (3H, t, $J=7.3$ Hz). MS (Cl^+ , CH_4) 418 ($\text{M}+\text{C}_2\text{H}_5$) $^+$, 390 ($\text{M}+\text{H}$) $^+$, 346 ($\text{M}-\text{NHCO}$) $^+$. TLC (3:1 EtOAc/hexane) $R_f=0.40$.
12. Energy minimizations were performed using Chem3DTM 3.1.2 on a Macintosh LC II computer equipped with FPU simulation software.

(Received in USA 24 October 1994; accepted 9 November 1994)